The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs \& symptoms of blepharitis and tear cytokine and eyelid bacterial load levels
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Central Maine Eye Care
Lewiston, Maine, United States
Ophthalmic Research Associates
Andover, Massachusetts, United States
Change in clinical signs and symptoms associated with blepharitis
Time frame: 8 weeks
Standard ocular safety assessments
Time frame: 4 weeks
Change in tear cytokine and eyelid bacterial load levels
Time frame: 4 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.